JPS6140204B2 - - Google Patents

Info

Publication number: JPS6140204B2
Authority: JP; Japan
Prior art keywords: melting point; component; lipid; mixture; melting
Prior art date: 1980-06-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP56098464A

Other languages

English (en)

Japanese (ja)

Other versions

JPS5738711A (en

Inventor

Augaruto Herumuuto

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Goedecke GmbH

Original Assignee

Goedecke GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-06-28

Filing date

1981-06-26

Publication date

1986-09-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6105792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPS6140204(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1981-06-26 Application filed by Goedecke GmbH filed Critical Goedecke GmbH

1982-03-03 Publication of JPS5738711A publication Critical patent/JPS5738711A/ja

1986-09-08 Publication of JPS6140204B2 publication Critical patent/JPS6140204B2/ja

Status Granted legal-status Critical Current

Links

238000002844 melting Methods 0.000 claims abstract description 72
230000008018 melting Effects 0.000 claims abstract description 69
239000000203 mixture Substances 0.000 claims abstract description 50
150000002632 lipids Chemical class 0.000 claims abstract description 28
238000000034 method Methods 0.000 claims abstract description 20
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
239000013543 active substance Substances 0.000 claims description 26
239000000126 substance Substances 0.000 claims description 18
230000003111 delayed effect Effects 0.000 claims description 10
238000010438 heat treatment Methods 0.000 claims description 9
239000000155 melt Substances 0.000 claims description 6
238000002156 mixing Methods 0.000 claims description 5
235000014113 dietary fatty acids Nutrition 0.000 claims description 4
239000000194 fatty acid Substances 0.000 claims description 4
229930195729 fatty acid Natural products 0.000 claims description 4
150000004665 fatty acids Chemical class 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 3
150000002191 fatty alcohols Chemical group 0.000 claims description 2
125000005456 glyceride group Chemical group 0.000 claims description 2
229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
239000011707 mineral Substances 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
235000013311 vegetables Nutrition 0.000 claims description 2
239000011149 active material Substances 0.000 abstract description 3
239000003826 tablet Substances 0.000 description 38
239000008187 granular material Substances 0.000 description 24
238000001816 cooling Methods 0.000 description 17
239000000843 powder Substances 0.000 description 14
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
239000008101 lactose Substances 0.000 description 9
229920002134 Carboxymethyl cellulose Polymers 0.000 description 8
235000021355 Stearic acid Nutrition 0.000 description 8
239000001768 carboxy methyl cellulose Substances 0.000 description 8
235000010948 carboxy methyl cellulose Nutrition 0.000 description 8
239000008112 carboxymethyl-cellulose Substances 0.000 description 8
239000000463 material Substances 0.000 description 8
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 8
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 8
239000008117 stearic acid Substances 0.000 description 8
235000019438 castor oil Nutrition 0.000 description 7
239000004359 castor oil Substances 0.000 description 7
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 7
239000002245 particle Substances 0.000 description 6
239000000654 additive Substances 0.000 description 5
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
OWMFSWZUAWKDRR-UHFFFAOYSA-N Norfenefrine hydrochloride Chemical compound [Cl-].[NH3+]CC(O)C1=CC=CC(O)=C1 OWMFSWZUAWKDRR-UHFFFAOYSA-N 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
-1 alkane carboxylic acids Chemical class 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
LRCXRAABFLIVAI-UHFFFAOYSA-N norfenefrine Chemical compound NCC(O)C1=CC=CC(O)=C1 LRCXRAABFLIVAI-UHFFFAOYSA-N 0.000 description 3
229960001856 norfenefrine Drugs 0.000 description 3
230000008961 swelling Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 2
WKACQPMBGWZDMR-UHFFFAOYSA-N Vincamin Natural products CC=C1/CN2CCC34CC2C1C(=C3Nc5ccccc45)C=O WKACQPMBGWZDMR-UHFFFAOYSA-N 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 2
229940088679 drug related substance Drugs 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 2
229960000201 isosorbide dinitrate Drugs 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000002994 raw material Substances 0.000 description 2
RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
241000220317 Rosa Species 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000004568 cement Substances 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000001934 delay Effects 0.000 description 1
238000005137 deposition process Methods 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
239000011796 hollow space material Substances 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
239000012943 hotmelt Substances 0.000 description 1
239000010514 hydrogenated cottonseed oil Substances 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000004898 kneading Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
238000003801 milling Methods 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
239000005445 natural material Substances 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000009711 regulatory function Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000007939 sustained release tablet Substances 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
150000005691 triesters Chemical class 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

JP9846481A 1980-06-28 1981-06-26 Manufacture of slow-release medicinal composition Granted JPS5738711A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE3024416A DE3024416C2 (de)	1980-06-28	1980-06-28	Verfahren zur Herstellung von Arzneimitteln mit retardierter Wirkstoff-Freisetzung

Publications (2)

Publication Number	Publication Date
JPS5738711A JPS5738711A (en)	1982-03-03
JPS6140204B2 true JPS6140204B2 (2)	1986-09-08

Family

ID=6105792

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP9846481A Granted JPS5738711A (en)	1980-06-28	1981-06-26	Manufacture of slow-release medicinal composition

Country Status (15)

Country	Link
US (1)	US4483847A (2)
EP (1)	EP0043254B1 (2)
JP (1)	JPS5738711A (2)
AT (1)	ATE7655T1 (2)
AU (1)	AU545279B2 (2)
CA (1)	CA1165691A (2)
DD (1)	DD159966A5 (2)
DE (2)	DE3024416C2 (2)
DK (1)	DK155711C (2)
ES (1)	ES8301625A1 (2)
FI (1)	FI76928C (2)
HU (1)	HU184862B (2)
IE (1)	IE51353B1 (2)
SU (1)	SU1360575A3 (2)
ZA (1)	ZA814094B (2)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5959632A (ja) *	1982-09-28	1984-04-05	Teikoku Chem Ind Corp Ltd	徐放性組成物
US4713245A (en) *	1984-06-04	1987-12-15	Mitsui Toatsu Chemicals, Incorporated	Granule containing physiologically-active substance, method for preparing same and use thereof
JPS6150912A (ja) *	1984-08-16	1986-03-13	Shionogi & Co Ltd	リポソ−ム製剤の製造法
US4755387A (en) *	1985-03-21	1988-07-05	The Procter & Gamble Company	Therapeutic particles
FR2581541B1 (fr) *	1985-05-09	1988-05-20	Rhone Poulenc Sante	Nouvelles compositions pharmaceutiques permettant la liberation prolongee d'un principe actif et leur procede de preparation
US4820523A (en) *	1986-04-15	1989-04-11	Warner-Lambert Company	Pharmaceutical composition
US4837381A (en) *	1986-08-11	1989-06-06	American Cyanamid Company	Compositions for parenteral administration and their use
US4822619A (en) *	1987-02-18	1989-04-18	Ionor, Inc.	Controlled release pharmaceutical preparation containing a gastrointestinal irritant drug
JP2668880B2 (ja) *	1987-06-23	1997-10-27	日本油脂株式会社	被覆アミノ酸類の製造方法
DE3737741A1 (de) *	1987-11-06	1989-05-18	Goedecke Ag	Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid
JP2681373B2 (ja) *	1988-07-18	1997-11-26	塩野義製薬株式会社	徐放性製剤の製造法
EP0418596A3 (en) *	1989-09-21	1991-10-23	American Cyanamid Company	Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5213810A (en) *	1990-03-30	1993-05-25	American Cyanamid Company	Stable compositions for parenteral administration and method of making same
IE61651B1 (en) *	1990-07-04	1994-11-16	Zambon Spa	Programmed release oral solid pharmaceutical dosage form
US5134016A (en) *	1990-10-31	1992-07-28	E. I. Du Pont De Nemours And Company	Fiber reinforced porous sheets
US5266331A (en) *	1991-11-27	1993-11-30	Euroceltique, S.A.	Controlled release oxycodone compositions
US5958459A (en) *	1991-12-24	1999-09-28	Purdue Pharma L.P.	Opioid formulations having extended controlled released
US5968551A (en)	1991-12-24	1999-10-19	Purdue Pharma L.P.	Orally administrable opioid formulations having extended duration of effect
US5478577A (en) *	1993-11-23	1995-12-26	Euroceltique, S.A.	Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
DE59302200D1 (de) *	1992-05-22	1996-05-15	Goedecke Ag	Verfahren zur herstellung retardierter arzneimittelzubereitungen
IL119660A (en) *	1993-05-10	2002-09-12	Euro Celtique Sa	Controlled release formulation comprising tramadol
US7740881B1 (en)	1993-07-01	2010-06-22	Purdue Pharma Lp	Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) *	1993-07-01	1999-11-30	Euro Celtique Sa	Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) *	1993-07-27	1999-03-09	Euro-Celtique S.A.	Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
KR100354702B1 (ko) *	1993-11-23	2002-12-28	유로-셀티크 소시에떼 아노뉨	약학조성물의제조방법및서방형조성물
US5891471A (en) *	1993-11-23	1999-04-06	Euro-Celtique, S.A.	Pharmaceutical multiparticulates
US5843480A (en) *	1994-03-14	1998-12-01	Euro-Celtique, S.A.	Controlled release diamorphine formulation
GB9422154D0 (en)	1994-11-03	1994-12-21	Euro Celtique Sa	Pharmaceutical compositions and method of producing the same
US5965161A (en)	1994-11-04	1999-10-12	Euro-Celtique, S.A.	Extruded multi-particulates
MX9707585A (es) *	1995-04-03	1997-12-31	Abbott Lab	Mezclas homogeneas de farmacos y aditivos de fusion a baja temperatura para liberacion controlada.
DE19522899C1 (de) *	1995-06-23	1996-12-19	Hexal Pharmaforschung Gmbh	Verfahren zum kontinuierlichen Ersintern eines Granulats
KR100508910B1 (ko) *	1995-10-17	2006-04-20	알티피 파마 코포레이션	불용성약물방출
US6465016B2 (en)	1996-08-22	2002-10-15	Research Triangle Pharmaceuticals	Cyclosporiine particles
US7255877B2 (en)	1996-08-22	2007-08-14	Jagotec Ag	Fenofibrate microparticles
DE19705538C1 (de) *	1997-02-14	1998-08-27	Goedecke Ag	Verfahren zur Trennung von Wirkstoffen in festen pharmazeutischen Zubereitungen
US5891476A (en) *	1997-12-22	1999-04-06	Reo; Joe P.	Tastemasked pharmaceutical system
ES2201673T3 (es) *	1998-02-11	2004-03-16	Rtp Pharma Corporation	Combinacion de esteroides y acidos grasos poiinsaturados para el tratamiento de estados inflamatorios.
US6979456B1 (en)	1998-04-01	2005-12-27	Jagotec Ag	Anticancer compositions
WO1999061001A1 (en)	1998-05-29	1999-12-02	Rtp Pharma Inc.	Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
US7097849B2 (en)	1998-08-19	2006-08-29	Jagotec Ag	Injectable aqueous dispersions of propofol
US6806294B2 (en)	1998-10-15	2004-10-19	Euro-Celtique S.A.	Opioid analgesic
WO2000030616A1 (en)	1998-11-20	2000-06-02	Rtp Pharma Inc.	Dispersible phospholipid stabilized microparticles
DE19918325A1 (de)	1999-04-22	2000-10-26	Euro Celtique Sa	Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US8663692B1 (en) *	1999-05-07	2014-03-04	Pharmasol Gmbh	Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
KR20020059653A (ko)	1999-10-29	2002-07-13	그린 마틴, 브라이언 쥐 테슬리	서방성 하이드로코돈 제형
CA2407027C (en)	2000-04-20	2011-02-15	Rtp Pharma Inc.	Improved water-insoluble drug particle process
US6634576B2 (en)	2000-08-31	2003-10-21	Rtp Pharma Inc.	Milled particles
US8586094B2 (en)	2000-09-20	2013-11-19	Jagotec Ag	Coated tablets
EP1337244A4 (en) *	2000-10-30	2006-01-11	Euro Celtique Sa	HYDROCODON FORMULATIONS WITH CONTROLLED RELEASE
ATE373471T1 (de) *	2000-12-27	2007-10-15	Ares Trading Sa	Lipidmikropartikel mittels kryogenischer mikronisierung
US7776314B2 (en)	2002-06-17	2010-08-17	Grunenthal Gmbh	Abuse-proofed dosage system
DE10300325A1 (de)	2003-01-09	2004-07-22	Hexal Ag	Granulat mit öliger Substanz, Herstellungsverfahren und Tablette
BRPI0407181A (pt)	2003-02-03	2006-02-07	Novartis Ag	Formulação farmacêutica
DE10361596A1 (de)	2003-12-24	2005-09-29	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de)	2004-07-01	2006-01-19	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US8075872B2 (en)	2003-08-06	2011-12-13	Gruenenthal Gmbh	Abuse-proofed dosage form
US20070048228A1 (en)	2003-08-06	2007-03-01	Elisabeth Arkenau-Maric	Abuse-proofed dosage form
DE10336400A1 (de)	2003-08-06	2005-03-24	Grünenthal GmbH	Gegen Missbrauch gesicherte Darreichungsform
RU2267318C1 (ru) *	2004-05-25	2006-01-10	Закрытое акционерное общество "ФАРМАПЭК"	Пролонгированный антиангинальный препарат изосорбида динитрата и способ его получения
HUE037643T2 (hu)	2004-06-12	2018-09-28	Collegium Pharmaceutical Inc	Visszaélésre nem alkalmas gyógyszerkészítmények
DE102004032049A1 (de)	2004-07-01	2006-01-19	Grünenthal GmbH	Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20080069871A1 (en) *	2006-07-21	2008-03-20	Vaughn Jason M	Hydrophobic abuse deterrent delivery system
DE102007011485A1 (de)	2007-03-07	2008-09-11	Grünenthal GmbH	Darreichungsform mit erschwertem Missbrauch
ES2441550T3 (es) *	2007-12-21	2014-02-05	Ludwig-Maximilians-Universität	Dispositivos extruidos con forma de varilla para la Iiberación controlada de sustancias biológicas a humanos y animales
WO2009092601A1 (en)	2008-01-25	2009-07-30	Grünenthal GmbH	Pharmaceutical dosage form
CA2723438C (en)	2008-05-09	2016-10-11	Gruenenthal Gmbh	Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
WO2011009602A1 (en)	2009-07-22	2011-01-27	Grünenthal GmbH	Hot-melt extruded controlled release dosage form
PE20120572A1 (es)	2009-07-22	2012-06-06	Gruenenthal Chemie	Forma de dosificacion de oxidacion estabilizada resistente a la manipulacion
US10668060B2 (en)	2009-12-10	2020-06-02	Collegium Pharmaceutical, Inc.	Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP2531176B1 (en)	2010-02-03	2016-09-07	Grünenthal GmbH	Preparation of a powdery pharmaceutical composition by means of an extruder
PE20131102A1 (es)	2010-09-02	2013-10-12	Gruenenthal Chemie	Forma de dosificacion resistente a manipulacion que comprende una sal inorganica
TWI516286B (zh)	2010-09-02	2016-01-11	歌林達股份有限公司	含陰離子聚合物之抗破碎劑型
LT2736495T (lt)	2011-07-29	2017-11-10	Grünenthal GmbH	Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
DK2736497T3 (da)	2011-07-29	2017-11-13	Gruenenthal Gmbh	Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel.
CA2864949A1 (en)	2012-02-28	2013-09-06	Grunenthal Gmbh	Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
RS57913B1 (sr)	2012-04-18	2019-01-31	Gruenenthal Gmbh	Farmaceutske dozne forme otporne na neovlašćenu upotrebu i naglo oslobađanje celokupne doze
US10064945B2 (en)	2012-05-11	2018-09-04	Gruenenthal Gmbh	Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10154966B2 (en)	2013-05-29	2018-12-18	Grünenthal GmbH	Tamper-resistant dosage form containing one or more particles
AR096438A1 (es)	2013-05-29	2015-12-30	Gruenenthal Gmbh	Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
MX368846B (es)	2013-07-12	2019-10-18	Gruenenthal Gmbh	Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo.
EP3073994A1 (en)	2013-11-26	2016-10-05	Grünenthal GmbH	Preparation of a powdery pharmaceutical composition by means of cryo-milling
JP2017518980A (ja)	2014-05-12	2017-07-13	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	タペンタドールを含む、改変防止即時放出カプセル製剤
US9872835B2 (en)	2014-05-26	2018-01-23	Grünenthal GmbH	Multiparticles safeguarded against ethanolic dose-dumping
MX382764B (es) *	2014-08-11	2025-03-13	Perora Gmbh	Metodo para la induccion de saciedad.
JP2018517676A (ja)	2015-04-24	2018-07-05	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	即時放出および溶媒抽出に対する耐性を有する改変防止製剤
US10842750B2 (en)	2015-09-10	2020-11-24	Grünenthal GmbH	Protecting oral overdose with abuse deterrent immediate release formulations
WO2017222575A1 (en)	2016-06-23	2017-12-28	Collegium Pharmaceutical, Inc.	Process of making more stable abuse-deterrent oral formulations
CA3131133C (en)	2016-11-10	2023-01-17	Medisca Pharmaceutique Inc.	Pharmaceutical compounding methods and systems
EP3492070A1 (en)	2017-11-30	2019-06-05	BIT Pharma GmbH	Process and device for preparing a solid dispersion

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2875130A (en) *	1956-11-20	1959-02-24	Smith Kline French Lab	Method of preparing sustained release particles and the product of the method
GB906422A (en) *	1958-05-02	1962-09-19	Wellcome Found	Improvements in and relating to prolonged acting pharmaceutical preparations
US3108046A (en) *	1960-11-25	1963-10-22	Smith Kline French Lab	Method of preparing high dosage sustained release tablet and product of this method
US3146167A (en) *	1961-10-05	1964-08-25	Smith Kline French Lab	Method of preparing sustained release pellets and products thereof
US3279998A (en) *	1962-06-22	1966-10-18	Smith Kline French Lab	Method of preparing sustained release tablets
GB1021924A (en) *	1962-06-22	1966-03-09	Smith Kline French Lab	Improvements in or relating to method of preparing sustained release tablets
US3308217A (en) *	1965-02-09	1967-03-07	Lowy Lawrence	Method of granulating materials for subsequent forming into tablets
US4132753A (en) *	1965-02-12	1979-01-02	American Cyanamid Company	Process for preparing oral sustained release granules
US3374146A (en) *	1966-04-18	1968-03-19	American Cyanamid Co	Sustained release encapsulation
US3487138A (en) *	1966-11-23	1969-12-30	Merck & Co Inc	Process for preparing a delayed release medicinal tablet
DE1617418C3 (de) *	1967-12-16	1980-01-24	Hoechst Ag, 6000 Frankfurt	Herstellung von festen Arzneimittelformen mit verzögerter Wirkstoffabgabe
SE335202B (2) *	1968-06-19	1971-05-17	Aco Laekemedel Ab
GB1312918A (en) *	1969-07-08	1973-04-11	Beecham Group Ltd	Veterinary treatment
DK121813B (da) *	1969-12-10	1971-12-06	C Mangen	Fremgangsmåde til fremstilling af tabletlignende doseringsenheder.
DE2426811A1 (de) *	1974-06-04	1976-01-08	Klinge Co Chem Pharm Fab	Verfahren zur herstellung von retard-tabletten

1980
- 1980-06-28 DE DE3024416A patent/DE3024416C2/de not_active Expired
1981
- 1981-06-17 ZA ZA814094A patent/ZA814094B/xx unknown
- 1981-06-22 FI FI811951A patent/FI76928C/fi not_active IP Right Cessation
- 1981-06-23 AU AU72069/81A patent/AU545279B2/en not_active Expired
- 1981-06-24 DK DK278381A patent/DK155711C/da not_active IP Right Cessation
- 1981-06-25 DD DD81231145A patent/DD159966A5/de unknown
- 1981-06-26 HU HU811873A patent/HU184862B/hu unknown
- 1981-06-26 CA CA000380767A patent/CA1165691A/en not_active Expired
- 1981-06-26 SU SU813304330A patent/SU1360575A3/ru active
- 1981-06-26 DE DE8181302895T patent/DE3163868D1/de not_active Expired
- 1981-06-26 ES ES503414A patent/ES8301625A1/es not_active Expired
- 1981-06-26 EP EP81302895A patent/EP0043254B1/en not_active Expired
- 1981-06-26 AT AT81302895T patent/ATE7655T1/de not_active IP Right Cessation
- 1981-06-26 IE IE1438/81A patent/IE51353B1/en not_active IP Right Cessation
- 1981-06-26 JP JP9846481A patent/JPS5738711A/ja active Granted
1983
- 1983-09-20 US US06/534,020 patent/US4483847A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JPS5738711A (en)	1982-03-03
SU1360575A3 (ru)	1987-12-15
FI76928C (fi)	1989-01-10
EP0043254B1 (en)	1984-05-30
ATE7655T1 (de)	1984-06-15
DE3024416A1 (de)	1982-01-21
CA1165691A (en)	1984-04-17
HU184862B (en)	1984-10-29
IE51353B1 (en)	1986-12-10
DE3024416C2 (de)	1982-04-15
DK278381A (da)	1981-12-29
AU7206981A (en)	1982-01-07
IE811438L (en)	1981-12-28
FI811951L (fi)	1981-12-29
AU545279B2 (en)	1985-07-11
DE3163868D1 (en)	1984-07-05
EP0043254A1 (en)	1982-01-06
DD159966A5 (de)	1983-04-20
ZA814094B (en)	1982-07-28
ES503414A0 (es)	1983-01-01
ES8301625A1 (es)	1983-01-01
FI76928B (fi)	1988-09-30
DK155711C (da)	1989-10-23
DK155711B (da)	1989-05-08
US4483847A (en)	1984-11-20

Publication	Publication Date	Title
JPS6140204B2 (2)	1986-09-08
US3279998A (en)	1966-10-18	Method of preparing sustained release tablets
US3670065A (en)	1972-06-13	Process for producing dosage units of a type resembling tablets
US3147187A (en)	1964-09-01	Sustained release pharmaceutical
US3374146A (en)	1968-03-19	Sustained release encapsulation
US4137300A (en)	1979-01-30	Sustained action dosage forms
US5104648A (en)	1992-04-14	High ibuprofen content granulations
US5453283A (en)	1995-09-26	Orally administered solvent-free pharmaceutical preparation with delayed active-substance release, and a method of preparing the preparation
EA012882B1 (ru)	2009-12-30	Фармацевтические лекарственные формы, содержащие липидную фазу
US3857933A (en)	1974-12-31	Process for the manufacture of a drug dosage form permitting controlled release of active ingredient
JPH0354083B2 (2)	1991-08-19
JPS58214333A (ja)	1983-12-13	粒状物
US3908003A (en)	1975-09-23	Enrobed solid hydrophobic tableting lubricants and compositions
US2895881A (en)	1959-07-21	Quinidine gluconate sustained medication tablet
JP2006517929A (ja)	2006-08-03	溶融アグロメレーションを用いてアグロメレートを製造する方法
DE1492123A1 (de)	1969-07-17	Verfahren zur Herstellung von Arzneipraeparaten in Tablettenform
JPH0789875A (ja)	1995-04-04	崩壊遅延防止錠剤
JP2004277431A (ja)	2004-10-07	粒状製剤及びその製造法
JP4063390B2 (ja)	2008-03-19	錠剤の製造方法
JPH03161448A (ja)	1991-07-11	油脂含有組成物
US20020132010A1 (en)	2002-09-19	Divalproex sodium dosage forms and a process for their production
JPH0324019A (ja)	1991-02-01	打錠用生薬配合粉末の製法と打錠法
RU2171673C1 (ru)	2001-08-10	Фармацевтическая композиция и способ ее получения
RU2289403C2 (ru)	2006-12-20	Фармацевтическая композиция на основе афобазола
JPH03167122A (ja)	1991-07-19	塩酸ベラパミルを含有する固体医薬品の製法及び固体医薬品